MNKD241220C7000
- 0.05
- -0.11-68.75%
MannKind Newsroom
MannKind Shares Are Falling Today: What's Going On?
MannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint
MannKind Announced Six-month Results From Its Phase 3 Inhale-1 Study Of Afrezza (Insulin Human) Inhalation Powder In Children And Adolescents (Aged 4-17 Years). MannKind Expects To Submit A Request For Supplemental New Drug Application Meeting With...
Express News | MannKind Corp: Primary Endpoint Was Non-Inferior Change in Hba1C Levels After 26 Weeks
Express News | MannKind Corp: Expects to Ship Product for Cipla Ltd. by End of 2025
CDSCO Approves Afrezza (Insulin Human) Inhalation Powder in India
MannKind Corporation's (NASDAQ:MNKD) Institutional Investors Lost 3.9% Last Week but Have Benefitted From Longer-term Gains
Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7
Oppenheimer Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $12
IntegriChain Revenue Optimization Experts to Speak at Informa's Pharma/BioTech GTN Summit
MannKind's Growth Momentum and Increased Confidence in Pipeline Elevate Buy Rating
Q3 2024 MannKind Corp Earnings Call
RBC Capital Sticks to Its Hold Rating for MannKind (MNKD)
Express News | MannKind Corp : RBC Raises Target Price to $7 From $5
MannKind (MNKD) Q3 2024 Earnings Call Transcript
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript Summary
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript
Express News | MannKind Corp : Qtrly Shr $ 0.04
MannKind: Q3 Earnings Snapshot
MannKind Corp. Q3 Profit Increases, Beats Estimates